Granite Point Capital Management, L.P. Altimmune, Inc. Transaction History

Granite Point Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 04, 2022	BUY	$10.67 - $22.41 $1.92 Million - $4.03 Million	180,000 New	180,000 $2.3 Million
Q4 2020 Feb 05, 2021	SELL	$7.84 - $14.22 $352,800 - $639,900	-45,000 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$9.93 - $33.26 $1.04 Million - $3.49 Million	-105,000 Reduced 70.0%	45,000 $594,000
Q2 2020 Aug 12, 2020	BUY	$2.9 - $10.71 $435,000 - $1.61 Million	150,000 New	150,000 $1.61 Million

186

39.4M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $336M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.